Cover Image

A novel strategy for emergency treatment of coronary perforations by placing a drug-eluting stent before sealing off the leakage with a covered stent to improve long-term outcomes in patients with coronary artery perforations

We aimed to investigate the safety, feasibility, and long-term results of drug-eluting stent implantation before covered stents for treating coronary artery perforation (CAP). Between 2015 and 2020, 12,733 patients undergoing percutaneous coronary intervention (PCI) were retrospectively analyzed. Th...

Full description

Saved in:
Bibliographic Details
Main Authors: Ayoub, Mohamed (Author) , Corpataux, Noé (Author) , Tajti, Péter (Author) , Behnes, Michael (Author) , Schupp, Tobias (Author) , Forner, Jan (Author) , Akın, Ibrahim (Author) , Westermann, Dirk (Author) , Rudolph, Volker (Author) , Mashayekhi, Kambis (Author)
Format: Article (Journal)
Language:English
Published: 26 October 2023
In: Journal of Personalized Medicine
Year: 2023, Volume: 13, Issue: 11, Pages: 1-11
ISSN:2075-4426
DOI:10.3390/jpm13111542
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/jpm13111542
Verlag, kostenfrei, Volltext: https://www.mdpi.com/2075-4426/13/11/1542
Get full text
Author Notes:Mohamed Ayoub, Noé Corpataux, Péter Tajti, Michael Behnes, Tobias Schupp, Jan Forner, Ibrahim Akin, Dirk Westermann, Volker Rudolph and Kambis Mashayekhi
Description
Summary:We aimed to investigate the safety, feasibility, and long-term results of drug-eluting stent implantation before covered stents for treating coronary artery perforation (CAP). Between 2015 and 2020, 12,733 patients undergoing percutaneous coronary intervention (PCI) were retrospectively analyzed. The primary endpoint was 1-year target lesion revascularization (TLR), whereas secondary endpoints included the rate of major adverse cardiac and cerebrovascular events (MACCE) and all-cause death at 1 year. A total of 159 patients with CAP were identified during the study period, of whom 47.2% (n = 75) were treated with a covered stent (CS group) because of complex and/or severe CAP and 84 (52.8%) without (non-CS group). In the majority of patients, emergency drug-eluting stent placement before covered stent implantation was feasible (n = 69, 82%). There were no significant differences among patients treated with or without a covered stent in terms of primary or secondary clinical endpoints: a similar rate of TLR (18.67% vs. 21.43%, p = 0.6646), MACCE (25.33% vs. 22.62%, p = 0.6887), and 1-year mortality (12.00% vs. 11.90%, p = 0.9853) were identified comparing cases with covered stent implantation and without. In conclusion, our study implicates that the use of covered stents for sealing coronary perforation might not impact the 1-year clinical outcome if used properly. Moreover, the emergent use of drug-eluting stents before covered stent implantation in CAP is a safe and effective method to avoid target lesion revascularization in patients treated with covered stents.
Item Description:Gesehen am 16.05.2024
Physical Description:Online Resource
ISSN:2075-4426
DOI:10.3390/jpm13111542

Similar Items